Filtered By:
Specialty: Neurology
Drug: Pradaxa

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 127 results found since Jan 2013.

Cardio Notes: Societies Issue Top 10 List
(MedPage Today) -- The American Heart Association and the American Stroke Association have compiled the top 10 advances in heart disease and stroke research of 2013, and the safety of dabigatran (Pradaxa) will be examined again.
Source: MedPage Today Neurology - January 6, 2014 Category: Neurology Source Type: news

Correspondence Embolic strokes of undetermined source: support for a new clinical construct–Authors' reply
The interesting and important observations summarised by Pascal Gratz and colleagues lend support to the embolic strokes of undetermined source (ESUS) construct developed in our recent Personal View. Two large, international randomised trials are underway that will compare new oral anticoagulants (dabigatran and rivaroxaban, respectively) with aspirin for secondary stroke prevention in ESUS cohorts, and assess the therapeutic implications of this novel construct. Finally, cryptogenic (of unknown cause) stroke will be the subject of these long-overdue, randomised trials that will shed light on this obscure, but common, entity.
Source: Lancet Neurology - September 16, 2014 Category: Neurology Authors: Robert G Hart, Hans-Christoph Diener, Stuart J Connolly Tags: Correspondence Source Type: research

Efficacy and Safety of Novel Oral Anticoagulants in Patients with Cervical Artery Dissections
We report on the use, safety, and efficacy of NOACs in the treatment of CAD. Methods: We retrospectively identified patients diagnosed with CAD at a single academic center between January 2010 and August 2013. Patients were categorized by their antithrombotic treatment at hospital discharge with a NOAC (dabigatran, rivaroxaban, or apixaban), traditional anticoagulant (AC: warfarin or treatment dose low-molecular weight heparin), or antiplatelet agent (AP: aspirin, clopidogrel, or aspirin/extended-release dypyridamole). Using appropriate tests, we compared the baseline medical history, presenting clinical symptoms and initi...
Source: Cerebrovascular Diseases - November 12, 2014 Category: Neurology Source Type: research

Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report
We describe a 75-year-old female patient with nonvalvular atrial fibrillation who presented with acute ischemic stroke during treatment with dabigatran 2 × 110 mg per day. After informed consent, we reversed the anticoagulant effects of dabigatran using idarucizumab and applied an intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (off-label use). An intracerebral hemorrhage was excluded after systemic thrombolysis. Despite the IVT, the patient’s clinical condition deteriorated and she developed an ischemic lesion in the right pons, the right thalamus and right cerebellum. To date, the literatu...
Source: Case Reports in Neurology - June 27, 2016 Category: Neurology Source Type: research

Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs
Atrial fibrillation (AF) is one of the most frequent causes of stroke. Secondary prophylaxis by oral anticoagulants (OACs) is recommended after stroke in patients with AF. For decades, vitamin-K antagonists (VKAs) were the only available drugs for OAC. In the last years, non-vitamin K antagonist oral anticoagulants (NOACs) like dabigatran, rivaroxaban, apixaban or edoxaban have been introduced as OAC drugs for patients with AF or venous thromboembolism, based on large randomized trials, and their use is recommended by various guidelines.
Source: Epilepsy Research - July 7, 2016 Category: Neurology Authors: Claudia St öllberger, Josef Finsterer Tags: Short communication Source Type: research

Risk of intracranial hemorrhage with direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled  trials
ConclusionAll DOACs had a lower risk of ICH than VKAs. In terms of the risk of ICH, DOACs were overall as safe as LMWHs, and apixaban and dabigatran were as safe as aspirin, but rivaroxaban was not. For secondary prevention stroke, the risk of ICH with DOACs was overall lower than warfarin and similar to aspirin, but it should be noted that compared with aspirin, rivaroxaban may increase the risk of ICH. This is the first pair-wise meta-analysis that compares the risk of ICH between DOACs and other antithrombotic drugs in detail across all diseases, which may have certain significance for patients with high risk of ICH to ...
Source: Journal of Neurology - February 17, 2021 Category: Neurology Source Type: research

Outcome after intracranial hemorrhage under dabigatran and reversal with idarucizumab versus under vitamin-K-antagonists – the RIC-ICH study
ConclusionThese results, based on data from routine clinical practice, suggest that in-hospital mortality after idarucizumab treatment is comparable to that in patients pretreated with VKA. Due to the low precision of estimates, the results must be interpreted with caution.
Source: Frontiers in Neurology - July 24, 2023 Category: Neurology Source Type: research

Letter by Kawada Regarding Article, "Dabigatran Versus Warfarin: Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation" Letters to the Editor
Source: Stroke - September 23, 2013 Category: Neurology Authors: Kawada, T. Tags: Anticoagulants Letters to the Editor Source Type: research

Imaging of Contrast Medium Extravasation in Anticoagulation-Associated Intracerebral Hemorrhage With Dual-Energy Computed Tomography Basic Sciences
Conclusions— Dual-energy computed tomography allows quantifying CE, as a marker of ongoing bleeding, in a model of anticoagulation-associated ICH. Dabigatran induces less CE in ICH than warfarin and consequently reduces risks of hematoma expansion. This constitutes a potential safety advantage of dabigatran over warfarin. Nevertheless, in case of warfarin anticoagulation, prothrombin complex concentrates reduce this side effect.
Source: Stroke - September 23, 2013 Category: Neurology Authors: Won, S.-Y., Schlunk, F., Dinkel, J., Karatas, H., Leung, W., Hayakawa, K., Lauer, A., Steinmetz, H., Lo, E. H., Foerch, C., Gupta, R. Tags: Coumarins, Other anticoagulants, Other Treatment, Acute Cerebral Hemorrhage, Intracerebral Hemorrhage Basic Sciences Source Type: research

Dabigatran-related Intracerebral Hemorrhage Resulting in Hematoma Expansion
We present a case that suggests that hematoma expansion may occur after NOAC-related ICH.
Source: Journal of Stroke and Cerebrovascular Diseases - October 7, 2013 Category: Neurology Authors: Claus Z. Simonsen, Thorsten Steiner, Anna Tietze, Dorte Damgaard Tags: Case Reports Source Type: research

Response to Letter Regarding Article, "Dabigatran Versus Warfarin: Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation" Letters to the Editor
Source: Stroke - February 24, 2014 Category: Neurology Authors: Hori, M., Ezekowitz, M. D., Reilly, P. A. Tags: Health policy and outcome research, Coumarins, Other anticoagulants, Acute Cerebral Hemorrhage, Acute Cerebral Infarction Letters to the Editor Source Type: research

Dabigatran -The Future Of Cortical Venous Thrombosis Therapy -A Case Series Study (P6.025)
ConclusionsAs these cases demonstrate, Dabigatran appears be effective and safe in the treatment of single cortical venous sinus thrombosis . However large scale randomized controlled trials will be required to confirm its efficacy as a therapeutic modality .Disclosure: Dr. Mathew has nothing to disclose. Dr. Alexander has nothing to disclose. Dr. Sarma has nothing to disclose. Dr. Nadig has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Mathew, T., Alexander, L., Sarma, G., Nadig, R. Tags: General Neurology VI Source Type: research

Do the Antithrombotic Therapy at the Time of Intracerebral Hemorrhage Influence Clinical Outcome? Analysis between the Difference of Antiplatelet and Anticoagulant Agents and Clinical Course
Background: It is controversial whether taking antiplatelet agents (APs) or anticoagulant agents (ACs) could influence clinical outcome after intracerebral hemorrhage (ICH).Methods: We retrospectively investigated 557 ICH patients between September 2008 and August 2013. We reviewed patients' characteristics, hematoma volume, deterioration (hematoma expansion, surgical hematoma evacuation, or death), and clinical outcome in modified Rankin Scale.Results: A total of 397 were classified as neither AP nor AC (“Nothing”), 81 as single AP (44 as aspirin [ASA], 22 as clopidogrel or ticlopidine [CLP/TIC], 7 as cilostazol, 8 as...
Source: Journal of Stroke and Cerebrovascular Diseases - June 23, 2014 Category: Neurology Authors: Takeshi Okada, Taizen Nakase, Masahiro Sasaki, Tatsuya Ishikawa Tags: Original Articles Source Type: research

Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient
Novel oral anticoagulants (NOACs) are the recent therapeutic breakthrough in the thromboprophylaxis of non-valvular atrial fibrillation (NVAF). There are currently three different molecules approved for NVAF: dabigatran, rivaroxaban and apixaban. All three agents have demonstrated at least non-inferiority at major clinical endpoints compared to warfarin with their major advantage being the fixed-dose regimen that necessitates no regular blood tests and protects patients from the disastrous effects of infra-therapeutic (embolism) or supra-therapeutic (hemorrhage) anticoagulation.
Source: Journal of the Neurological Sciences - September 14, 2014 Category: Neurology Authors: Apostolos Safouris, Anne Demulder, Nikos Triantafyllou, Georgios Tsivgoulis Tags: Letter to the Editor Source Type: research

Does Dabigatran Increase the Risk of Delayed Hematoma Expansion in a Rat Model of Collagenase-Induced Intracerebral Hemorrhage?
This study aims to clarify whether dabigatran increases the risk of delayed hematoma expansion in a rat ICH model.
Source: Journal of Stroke and Cerebrovascular Diseases - November 25, 2014 Category: Neurology Authors: Shunsuke Tanoue, Joji Inamasu, Masayuki Yamada, Hiroshi Toyama, Yuichi Hirose Source Type: research